TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06782490: A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatm

Sponsor: Celgene · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$465,600

Rescue Site Savings

+$310,400

Unlock Full NCT06782490 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06782490 Rescue Dossier →